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Background. The aim of this systematic review and meta-analysis was to evaluate the benefit of 
platelet-rich plasma (PRP) in non-surgical orthopaedic procedures. 
Material and methods. We searched the Cochrane Wounds Specialized Register, CENTRAL, 
MEDLINE (through PUBMED), Embase, and SCOPUS. We also searched clinical trials registries 
for ongoing and unpublished studies and checked reference lists to identify additional studies. 
Results. We found 36 randomised controlled trials (2,073 patients) that met our inclusion criteria. 
The included studies mostly had small numbers of participants (from 20 to 225). Twenty-eight studies 
included patients with lateral epicondylitis or plantar fasciitis. PRP was compared to local steroids 
injection (19 studies), saline injection (6 studies), autologous whole blood (4 studies), local anaesthetic 
injection (3 studies), dry needling injection (3 studies), and to other comparators (4 studies). Primary 
outcomes were pain and function scores, and adverse events. On average, it is unclear whether or not 
use of PRP compared to controls reduces pain scores and functional score at short- (up to 3 months) 
and medium- (4-6 months) term follow-up. The available evidence for all the comparisons was rated 
as very low quality due to inconsistency, imprecision, and risk of bias in most of the selected studies. 
There were no serious adverse events related to PRP injection or control treatments. 
Conclusions. The results of this meta-analysis, which documents the very marginal effectiveness of 
PRP compared to controls, does not support the use of PRP as conservative treatment in orthopaedics.
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Introduction
Platelet-rich plasma (PRP) is a mixture of highly 
concentrated platelets and associated growth factors. 
It is obtained from whole blood through a 2-phase 
centrifugation process: the first for the separation of 
blood components, and the second for the final PRP 
production. There are currently over 40 commercial 
systems that have been developed to concentrate 
autologous whole blood into a platelet-rich substance1. 
Besides platelets, PRP contains some inflammatory cells 
(i.e. monocytes and polymorphonuclear neutrophils) and 
large amounts of proteins, including platelet-derived 
growth factor (PDGF), transforming growth factor beta 
(TGF-b), vascular endothelial growth factor (VEGF), 
epithelial growth factor (EGF), and adhesion molecules 
(i.e. fibrin, fibronectin and vitronectin)2-4. Such growth 
factors and cells have been shown to promote cell 
recruitment, proliferation and angiogenesis, which 
may be implicated in tissue regeneration and healing5-8. 
Thanks to these biological regenerative properties, 
a number of investigators have studied the potential 
clinical benefit of PRP, also from human umbilical cord 
blood7,8, in a wide array of conditions ranging from 
dermatological disorders to oromaxillofacial surgery9-11 
In addition, a number of randomised controlled 
clinical trials (RCTs) have evaluated PRP use in 
the orthopaedic setting, particularly for tendon and 
ligament injuries, and several systematic reviews and 
meta-analysis have been subsequently published, 
although with contrasting results12-20. With the aim of 
elucidating this controversial issue, we have performed 
a systematic review and meta-analysis on the efficacy of 
PRP as conservative treatment in orthopaedics. 
Material and methods
This systematic review was conducted according to 
the recommended PRISMA checklist guidelines21.
Search strategy 
A computer-assisted literature search of the 
MEDLINE (through PUBMED), EMBASE, SCOPUS, 
OVID and Cochrane Library electronic databases was 
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performed (last search April 30, 2018) to identify 
RCTs on the conservative non-surgical use of PRP in 
orthopaedics. A combination of the following text words 
was used to maximise search specificity and sensitivity: 
"platelet rich plasma", "conservative", "orthopaedics", 
"tendon", "tendinopathy", "tendinitis", "ligament", 
"randomized clinical controlled trials", "Achilles 
tendinopathy", "plantar fasciitis", "lateral epicondylitis", 
"tennis elbow", "patellar tendinopathy" and "rotator cuff 
tendinopathy". In addition, we checked the reference 
lists of the most relevant items (original studies and 
reviews) in order to identify potentially eligible studies 
not captured by the initial literature search. 
Study selection and inclusion criteria
Study selection was performed independently by two 
reviewers (MF and MC), with disagreements resolved 
through discussion and on the basis of the opinion of a 
third reviewer (CM). Eligibility assessment was based 
on the title or abstract and on the full text if required. 
Articles were eligible if they reported either in the 
title or in the abstract the use of PRP in orthopaedics. 
Only RCTs published in full in English were included 
in this systematic review and meta-analysis. Studies 
enrolling less than 10 patients were excluded, along with 
RCTs evaluating platelet-poor plasma and autologous 
conditioned plasma. 
For the purpose of this systematic review, trials 
evaluating the role of PRP in surgical orthopaedic 
procedures were excluded. We selected five groups of 
disorders: 
- lateral epicondylitis;
- Achilles tendinopathy;
- plantar fasciitis;
- patellar tendinopathy;
- rotator cuff tendinopathy.
Types of interventions
Trials evaluating platelet-poor plasma and autologous 
conditioned plasma were excluded. We compared 
intralesional, injected PRP preparation with:
- local steroids injection; 
- placebo injection; 
- whole blood injection;
- local anaesthetic injection; 
- exercise and other physical therapies (e.g. low-dose 
radiation therapy, eccentric loading programme); 
- any other medications given locally or systemically 
aimed at treating pain; and 
- combinations of the active interventions listed above.
Outcomes
Primary outcomes included pain as measured by 
standard validated pain scale, e.g. Visual Analogue Score 
(VAS) is a continuous scale comprised of a horizontal 
(HVAS) or vertical (VVAS) line, usually 10 centimetres 
(100 millimetres, mm) in length, anchored by 2 verbal 
descriptors, one for each symptom extreme (higher 
scores = worse pain). In order to compare the results 
of the studies, the different scales used were converted 
into mm. Functional measurement by any standard 
validated scale, such as the American Orthopedic Foot 
and Ankle Society Score (AOFAS), and Disabilities 
of the Arm, Shoulder and Hand (DASH) score were 
also included. With functional scale, a higher scale 
indicated better function. Serious adverse events (e.g. 
infection at the injection site, heel fat pad atrophy, and 
plantar fascia rupture) were also evaluated. Secondary 
outcomes included tendon thickness in mm evaluated 
by ultrasounds.
The outcome measures were sub-grouped into two-
time periods: short-term (within 3 months from the 
intervention) and medium-term (from 4 to 6 months). A 
long-term period (12 months) was not evaluated because 
few studies reported it and a pooled analysis of data was 
not possible. If multiple time points were reported within 
our time frames, we extracted the latest time point (e.g. 
if data were reported at four weeks, five weeks, three 
months and six months, we extracted outcomes at three 
and six months).
Data collection and analysis
For each RCT included in the systematic review, 
the following data were extracted by two reviewers 
(MF and MC) independently: first author, year of 
publication, orthopaedic disease, details of intervention 
in study and control group, sample size, mean age and 
male:female ratio (PRP and control groups), outcome 
measurements, follow-up period, and main results. 
Measures of treatment effect were mean differences 
(MD) together with 95% confidence intervals (CI) for 
continuous outcome measures (e.g. pain scores and 
functional improvement). For this measure, the score 
had to be reported as mean and standard deviation (SD); 
when studies reported other dispersion measures such 
as standard error (SE) of the mean or 95% Confidence 
Interval (CI) of the mean, we calculated the SD in order 
to perform the relevant meta-analytical pooling. We 
used final scores in preference to change in scores or 
cumulative incidence such as reduction of pain score 
reaching a predetermined size (for example ≥25% 
or ≥50%, indicated as "success"). Disagreement was 
resolved by consensus and by the opinion of a third 
reviewer (CM), if necessary.
The study weight was calculated using the Mantel-
Haenszel method. We assessed statistical heterogeneity 
using t2, Cochran's Q and I2 statistics. The I2 statistic 
describes the percentage of total variation across trials 
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that is due to heterogeneity rather than sampling error. 
In the case of no heterogeneity (I2=0), studies were 
pooled using a fixed-effects model. Where values of 
I2 were >0, a random-effects analysis was undertaken. 
All calculations were made using Stata 15.1, R version 
3.4.3, and REVMAN 522.
We undertook subgroup analysis for duration of 
follow-up (short-term and medium-term, as defined 
above) and, where appropriate, for type of control 
intervention (e.g. PRP vs local steroids injection). 
Assessment of risk of bias in included studies 
Two review Authors (MF, MC) independently 
assessed the risk of bias of each included study following 
the domain-based evaluation described in the Cochrane 
Handbook for Systematic Reviews of Interventions23. 
They discussed any discrepancies and achieved 
consensus on the final assessment. The Cochrane "Risk 
of bias" tool addresses six specific domains: sequence 
generation, allocation concealment, blinding, incomplete 
data, selective outcome reporting, and other issues 
relating to bias. For the selective reporting domain, we 
added an item for the outcome "adverse events" because 
reporting was inadequate only for this outcome. We have 
presented our assessment of risk of bias using two "Risk 
of bias" summary figures: 1) a summary of bias for each 
item across all studies; and 2) a cross-tabulation of each 
trial by all of the "Risk of bias" items.
Summary of findings tables
We used the principles of the GRADE system to 
assess the quality of the body of evidence associated 
with specific outcomes and constructed a summary 
of findings table using REVMAN 524. These tables 
present key information concerning the certainty 
of the evidence, the magnitude of the effects of the 
interventions examined, and the sum of available data 
for the main outcomes25. The summary of findings 
tables also includes an overall grading of the evidence 
related to each of the main outcomes using the GRADE 
approach, which defines the certainty of a body of 
evidence as the extent to which one can be confident that 
an estimate of effect or association is close to the true 
quantity of specific interest. The certainty of a body of 
evidence involves consideration of within-trial risk of 
bias (methodological quality), directness of evidence, 
heterogeneity, precision of effect estimates, and risk of 
publication bias27.
When evaluating the "Risk of bias" domain, we 
down-graded the GRADE assessment when we classified 
a study as being at high risk of bias for one or more of 
the following domains: selection, attrition, performance, 
detection, reporting, and other bias; or when the "Risk 
of bias" assessment for selection bias was unclear (this 
was classified as unclear for either the generation of the 
randomisation sequence or the allocation concealment 
domain). For the outcomes VAS, AOFAS and DASH, 
we down-graded for high risk of bias in performance and 
detection domains, since we judged that these outcomes, 
self-reported by patients or collected by physicians to 
help standardise the assessments of patients with these 
disorders, are likely to be influenced by lack of blinding. 
The following outcomes have been presented in the 
summary of findings table: i) pain outcomes: VAS at 
3 and 6 months of follow-up; ii) functional outcome: 
AOFAS at 3 and 6 months of follow-up; iii) serious 
adverse events (0-24 months).
Results
A total of 5,577 articles were identified after the 
initial electronic and manual search (Figure 1). Of 
these, 5,402 were excluded because they focused on 
other topics. Thus, 175 potentially relevant articles were 
selected and the next screening led to the exclusion of 
139 additional studies (reviews, protocols of RCTs, 
non-randomised studies, duplicates, studies containing 
no informative data). Among RCTs reporting different 
follow-up of the same trial27-30, we included only the last 
published update28,30. Thirty-six randomised studies28,30-64 
were included in the systematic review (see Table I for 
main characteristics and results of the included studies). 
Overall, 2,337 patients were enrolled in the 36 RCTs 
selected for the review. Of the 36 studies included in the 
systematic review, 11 were conducted in patients with 
lateral epicondylitis28,31,32,37,40,41,45,47-49,51, 14 in patients 
with plantar fasciitis38,43,44 46,50,52-55,58,60,62-64, 4 in patients 
with Achilles tendinopathy30,36,56,61, 3 in patients with 
Figure 1 - Flow chart of the inclusion of the studies. 
 RCT: randomised controlled clinical trials.
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rotator cuff tendinopathy34,39,57, 2 in patients with patellar 
tendinopathy35,42, and one58 in patients with shoulder 
impingement syndrome; one of these studies33 included 
both elbow tendinopathy and plantar fasciitis patients. 
In the 36 studies, PRP was compared to local steroids 
injection (19 studies)28,33,37,38,44,46-54,57,60,61,64, to saline 
injection (6 studies)30,34,37,56,61,62, to autologous whole 
blood (4 studies)31,32,40,58, to local anaesthetic injection (3 
studies)41,43,45, to dry needling injection (3 studies)39,42,63, 
and others comparators (4 studies)35,36,55,59 (Table I). The 
outcomes more commonly reported were: VAS, AOFAS, 
DASH, a miscellanea of other scores (see Table I). 
Risk of bias in included studies
Thirty-four studies (94%) were at high risk of bias 
for one or more domains, and 28 studies (77%) were at 
unclear risk of bias for one or more domains; 2 studies34,39 
were judged at low risk of bias in all the domains (Figure 
2A and B).
Allocation
We assessed 3 studies as being at high risk of 
selection bias, as randomisation was by alternating 
the 2 treatments, so the intervention allocations could 
have been foreseen in advance31,43,50. The reports of 
another 22 studies were unclear as far as random 
sequence generation and/or allocation concealment 
were concerned, while 11 studies were at low risk of 
selection biases.
Blinding
Twenty-one studies (58%) reported as open label, 
and these were graded as high risk of performance bias 
(blinding of participants and personnel). Five studies 
were graded at unclear risk of detection bias due to 
the fact that they did not provide information to permit 
judgement about "high" or "low" risk of bias related to 
the blinding of participants and personnel31,36,42,43,55. Ten 
studies were reported as double blind28,30,34 39,41,42,51,52,60,61. 
Nineteen studies were graded at low risk of detection 
bias due to the fact that the assessor was blinded to 
treatment allocation; 16 studies were graded at unclear 
risk of detection bias due to the fact that they did not 
provide information to permit judgement about "high" 
or "low" risk of bias related to the blinding of outcome 
assessors; one study65 was graded at "high risk" of bias.
Incomplete outcome data
Three studies36,55,64 were judged at high risk of 
attrition bias because there was a high proportion of 
enrolled subjects who left the study due to unsatisfactory 
effect of the initial treatment. Another 3 studies43,47,51 
were judged at unclear risk of bias. The remaining 
studies were judged at low risk of bias.
Figure 2 -  A) Risk of bias graph and (B) summary. 
 PRP: Platelet-rich plasma; SD: standard deviation; IV: 
intravenous; CI: Confidence Interval.
A
B
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Selective reporting
Selective reporting was low in all included studies 
for all the outcomes except adverse events. For the 
outcome adverse events, 26 out of 36 trials (72%) were 
judged at high risk of bias. The reporting of adverse 
events was generally inadequate, and 14 trials did 
not mention complications of treatment at all. Where 
adverse events were reported, these often consisted of 
short statements of the absence of adverse events in the 
study results or discussion without any indication of 
systematic recording. 
Other potential sources of bias
We judged five studies to be at high risk for 
other sources of bias: four because of unbalance at 
baseline28,44,53,54 and one64 because it did not provide 
information on the randomisation process despite 
enrolling 30 patients in the experimental group and 
50 in the control group.
Effects of interventions
For the summary of findings for the main comparison, 
see Table II, Figures 3 and 4, and Online supplementary 
content (Figures S1-S10).
Lateral epicondylitis 
Data from seven studies investigating PRP for lateral 
epicondylitis reported mean and SD for pain and/or 
functional measure scales28,31,33,40,48,49,51. The results for 
VAS at 3 and 6 months in PRP and any control groups 
are presented in Figures 3 and 4. At 3 months, pooled 
data from 6 trials (328 patients) showed no clear 
between group differences in VAS (MD −2.86; 95% CI: 
−8.57/2.85; I²=80%); very low-quality evidence down-
graded for serious risk of bias (particularly selection and 
performance bias), for inconsistency (due to substantial 
heterogeneity), and for imprecision (95% CIs include 
line of no effect). (See summary of findings in Table II). 
At 6 months, pooled data from 3 trials (158 patients) 
showed slightly better pain scores of PRP compared to 
control (MD −12.97; 95% CI: −20.61/−5.34; I²=78%); 
very low-quality evidence, down-graded twice for 
serious risk of bias (selection, performance and other 
bias), once for inconsistency. The results were much 
the same in subgroup analyses of studies with steroids 
as control (Online supplementary content, Figures S1 
and S2). At 3 months, pooled data from four trials (260 
patients) showed no clear between-group differences 
in VAS (MD 0.67; 95% CI: −2.61/3.95; I²=0%); very 
low-quality evidence, down-graded for serious risk of 
biases and serious imprecision. At 6 months, pooled data 
from 2 trials (130 patients) showed slightly better pain 
scores of PRP compared to control (MD −16.98; 95% 
CI: −26.50/−7.47; I²=57%); very low-quality evidence 
was down-graded (for serious risk of biases and for 
inconsistency).
Elbow pain was also reported as DASH score in 
4 studies (200 patients)28,33,49,51. At 3 months, DASH 
did not change significantly between groups (Online 
supplementary content, Figures S3 and S4). At 6 months, 
PRP showed slightly better pain scores compared to 
any control (MD −7.53; 95% CI: −9.11/−5.95) and in 
the subgroup analysis versus steroids (MD −8.17; 95% 
CI: −10.03/−6.31) (Online supplementary content, 
Figures S5 and S6). All these comparisons were graded 
as very low-quality evidence due to serious risk of bias 
(selection, performance and other bias), imprecision (at 
3 months), and inconsistency.
Plantar fasciitis 
Data from 15 studies investigating PRP for plantar 
fasciitis reported mean and SD for pain and/or functional 
measure scales33,38,43,44,46,50,52-55,58,60,62-64. The results for VAS at 
3 months (8 studies, 420 patients) and 6 months (6 studies, 
300 patients) in PRP and any control groups are presented 
in Figures 3 and 4. Pooled data showed slightly better pain 
scores in PRP treated group at 6 months (MD −7.87; 95% 
CI: −14.90/−0.85; I²=89%), but not at 3 months (MD −8.25; 
95% CI: −17.70/1.20; I²=94%); very low-quality evidence 
down-graded for serious risk of biases, inconsistency and 
serious imprecision at 3 months (Table II). Likewise, in 
subgroup analyses of studies with steroids as control (Online 
supplementary content, Figures S1 and 2S), pooled data 
showed slightly better pain scores in PRP treated group 
both at 6 months (5 trials, 260 patients; MD −9.47; 95% 
CI: −17.98/−0.97; I²=92%;) but not at 3 months (8 studies, 
420 patients; MD −8.95; 95% CI: −17.70/1.20; I²=94%); 
very low-quality evidence, down-graded for serious risk of 
biases, inconsistency and serious imprecision at 3 months. 
The most commonly reported function measure was 
AOFAS; all these studies were conducted in plantar fasciitis 
patients and had local steroids injection as control group. 
Both at 3 months (4 studies, 178 patients)44,46,52,60 and at 6 
months (5 studies, 218 patients)44,46,52,55,60, AOFAS did not 
change significantly between the PRP and steroids group 
(MD, 4.26; 95% CI: −5.96/12.47; and 4.25; 95% CI: 
−5.92/14.42, respectively) (Online supplementary content, 
Figures S7 and S8). All these comparisons were graded as 
very low-quality evidence due to risk of bias, imprecision 
and inconsistency. As shown in Table I, there were other 
functional measurements included as outcome measures 
reported in the included studies, e.g. Foot Health Status 
Questionnaire (FHSQ), Mayo clinic performance index for 
elbow (MCPIE), maximum grip strength (MGS), and others, 
but because few (1 or 2) studies reported them, we decided 
not to conduct a quantitative synthesis for these outcomes. 
Four studies reported plantar fascia thickness measured by 
ultrasounds50,55,58,63. The results at 3 months (3 studies, 112 
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PRP in orthopaedics
Figure 4 - Forest plot of Visual Analogue Score (VAS) at 6 months.
Figure 3 - Forest plot of Visual Analogue Score (VAS) at 3 months..
patients) and 6 months (4 studies, 152 patients) showed no 
clear between-group differences (Online supplementary 
content, Figures S9 and S10). All these comparisons were 
graded as very low-quality evidence due to risk of bias and 
serious imprecision (112 patients from 3 trials).
Other tendinopathies 
Data from 4 studies (151 patients) investigating PRP 
for a variety of tendinopathies (patellar tendinopathy42, 
jumper's knee35, subacromial impingement syndrome59, 
and rotator cuff tears57) reported mean and SD for pain 
measure scales. The results at 3 and 6 months showed 
no clear between-group differences in VAS in the 
cumulative analysis (Figures 3 and 4).
Adverse events
In 22 studies (1,265 participants), no participant 
was reported to have developed any serious events (e.g. 
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application site infections, heel fat pad atrophy, and 
plantar fascia rupture) in the follow-up period (from 
1.5 to 24 months) in either PRP or control groups. 
Most trials did not describe monitoring processes for 
identifying or recording complications; and usually 
limited the reporting to a single statement regarding 
their absence. This comparison was graded as very 
low-quality evidence, and was down-graded once 
due to serious risk of bias (especially reporting bias) 
and twice for very serious imprecision (no events), 
reflecting the fact that numbers were not sufficient 
to detect rare events.
Other less serious, short-term adverse events, 
mostly post-injection pain, were reported in 6 trials. 
In one study, comparing PRP to dextrose prolotherapy 
for the treatment of chronic recalcitrant plantar 
fasciitis44, it was reported that most patients in both 
groups reported local pain or discomfort that started 
on the day of injection and subsided gradually 
afterwards. Likewise, an initial worsening of pain 
because of the activation of the inflammation cycle 
was observed in patients with lateral epicondylitis 
receiving PRP28; this usually lasted 1-2 weeks. Local 
pain or discomfort were also reported from another 
trial in most of the patients receiving PRP for lateral 
epicondylitis31. Pain at the site of injection was also 
reported in a small proportion of patients receiving 
PRP or controls in 3 studies35,37,41.
Discussion
Since its first development in the 1980s, PRP 
therapy has been gaining popularity, and orthopaedics 
immediately seemed to be the ideal sector in which to test 
the regenerative potential of this technology3. Since then, 
PRP has been used in the clinic to promote healing in a 
wide array of musculoskeletal disorders18. However, in 
spite of this extensive experience, relatively few studies 
have been conducted on the use of PRP as conservative 
treatment in orthopaedics. A recently published meta-
analysis which evaluated the clinical impact of PRP 
on tendinopathy compared to placebo or dry needling 
injections did not demonstrate a significantly greater 
clinical benefit for PRP at a 6-month follow-up65. In 
addition, a 2014 meta-analysis found no evidence that 
PRP was effective in chronic lateral epicondylitis66.
In the present meta-analysis, the largest published 
so far on this issue, we found a very low quality of 
evidence that PRP injection may not result in lower 
pain and function scores in the short- (1-3 months) 
and medium- (4-6 months) term follow-up, although 
a marginal benefit at medium-term follow-up (4-6 
months) for the VAS outcome was observed. In most 
of the comparisons, the 95% CI crossed the line of no 
benefit, and at best indicates the possibility of a very 
marginal clinical benefit. Difference in pain is a measure 
often derived from a 100 mm VAS. The minimal 
clinically important difference (MCID) between pre- 
and post-intervention is taken as 8 mm for average pain 
and 19 mm for first step pain67. Our findings show that 
the mean VAS score in the PRP group was 2.86 mm 
lower than in the control group on short-term follow-
up, and 12.97 mm lower at medium-term follow-up in 
lateral epicondylitis, and 8.25 mm lower at short-term 
follow-up, and 7.87 mm lower at medium-term follow-
up in plantar fasciitis; these are differences that can be 
regarded as clinically marginal.
The quantitative analysis conducted in this systematic 
review has, however, several limitations which do not 
allow us to draw definite conclusions on the PRP 
efficacy in this setting. The first limitation is certainly the 
heterogeneity of the studies evaluated, particularly in the 
efficacy outcomes. Another important limitation of this 
meta-analysis is that we were not able to determine the 
long-term (>12 months) effect of PRP due to the lack of 
enough time points in the studies evaluated. It is indeed 
possible, as claimed by some investigators68, that the 
best clinical benefit of PRP application in orthopaedics 
can occur in the long-term period. Finally, we would 
like to outline the lack of standardisation for PRP 
production among the different studies, which makes 
the PRP products heterogeneous and qualitatively 
very different from each other, and this limits the 
validity of an inter-studies comparison. 
Further, adequately powered, randomised trials are 
needed to better define potential indications, long-term 
benefit, and optimal treatment protocols of PRP as 
conservative treatment in orthopaedics. These studies 
should also perform an adequate cost-benefit analysis 
of PRP therapy compared with other standard, less 
expensive, treatments. 
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